Generic placeholder image

Current Molecular Pharmacology

Editor-in-Chief

ISSN (Print): 1874-4672
ISSN (Online): 1874-4702

Bevacizumab and Angiogenesis Inhibitors in the Treatment of CNS Metastases: The Road less Travelled

Author(s): Irina Veytsman, Jeanny B. Aragon-Ching and Sandra M. Swain

Volume 5, Issue 3, 2012

Page: [382 - 391] Pages: 10

DOI: 10.2174/1874467211205030007

Price: $65

Abstract

The incidence of central nervous system (CNS) metastases secondary to solid tumors is increasing. As more effective systemic therapy is being used in patients with solid tumors, patients with cancer live longer and are ultimately at higher risk for CNS metastases. However, CNS metastases remain challenging to treat because of limited available therapeutic options. This article reviews mechanisms of CNS metastases, the use of bevacizumab and other angiogenesis inhibitors in the treatment of recurrent and front-line CNS metastases, as well as emerging issues of resistance to antiangiogenic therapy.

Keywords: Angiogenesis, angiogenesis inhibitors, bevacizumab, CNS neoplasm


Rights & Permissions Print Export Cite as
© 2023 Bentham Science Publishers | Privacy Policy